SERNIVO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SERNIVO (SERNIVO).
SERNIVO (clobetasol propionate) is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects through induction of phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
| Metabolism | Clobetasol propionate is metabolized primarily in the liver via ester hydrolysis and subsequent conjugation. The primary metabolic pathway involves hydrolysis of the propionate ester to form clobetasol, followed by glucuronidation and sulfation. |
| Excretion | Primarily renal excretion of inactive metabolites; <5% unchanged. Minor biliary/fecal elimination. |
| Half-life | Approximately 3 hours (parent drug); clinical duration extended via formulation. |
| Protein binding | Approximately 70-80% bound to corticosteroid-binding globulin and albumin. |
| Volume of Distribution | Not reported for topical formulation; systemic absorption minimal. |
| Bioavailability | Topical: negligible systemic bioavailability (<1%) with intact skin. |
| Onset of Action | Topical: within 2 weeks of daily application for plaque psoriasis. |
| Duration of Action | Once-daily application for psoriasis; therapeutic effect maintained with continued use. |
| Molecular Weight | 466.97 |
Apply a thin layer to affected area twice daily for up to 2 weeks.
| Dosage form | SPRAY |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dosage adjustment recommended; use with caution due to potential age-related skin atrophy. |
| 1st trimester | No well-controlled studies in pregnant women. Animal studies have shown teratogenic effects at high doses. Use only if potential benefit justifies risk to fetus. |
| 2nd trimester | Corticosteroids can cause fetal growth restriction and hypothalamic-pituitary-adrenal axis suppression. Use only if clearly needed. |
| 3rd trimester | Extended use may lead to neonatal adrenal suppression. Avoid use near term if possible. |
Clinical note
Comprehensive clinical and safety monograph for SERNIVO (SERNIVO).
| Placental transfer | Topical corticosteroids can be absorbed percutaneously and cross the placenta. The degree of placental transfer depends on the amount absorbed systemically. Clobetasol propionate has potential for significant transfer with extensive or prolonged use. |
| Breastfeeding | Systemic corticosteroids are excreted in breast milk in small amounts. SERNIVO (clobetasol propionate) is a potent topical corticosteroid; however, absorption is minimal with appropriate use. Caution is advised if applied to large areas or for prolonged periods. Consider applying after breastfeeding or using a non-fluorinated alternative. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Known hypersensitivity to clobetasol propionate or any component of the formulationUntreated bacterial, fungal, or viral skin lesions
| Precautions | Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria., Pediatric patients may be more susceptible to systemic toxicity due to larger skin surface-to-body weight ratio., Prolonged use may result in atrophy of the skin, striae, and telangiectasias., Use on face, intertriginous areas, or under occlusion may increase systemic absorption., Do not use in patients with known hypersensitivity to clobetasol propionate or any component of the formulation. |
| Food/Dietary | No significant food interactions known. Avoid grapefruit juice if taking concomitant medications metabolized by CYP3A4, as clobetasol is partially metabolized by CYP3A4, though clinical relevance is minimal. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | SERNIVO (clobetasol propionate) is a topical corticosteroid. Systemic absorption is low with topical use, but prolonged or extensive application may increase risk. Animal studies show corticosteroids can cause teratogenicity (cleft palate, growth restriction). Human data on topical use in pregnancy are insufficient. Use only if potential benefit justifies risk. First trimester: consider risk of cleft palate; second/third trimester: risk of fetal growth restriction and adrenal suppression. |
| Fetal Monitoring | Monitor for signs of maternal adrenal suppression (fatigue, hypotension) if large areas are treated or occlusive dressings used. Fetal monitoring includes ultrasound for growth restriction if prolonged use. Newborns should be monitored for signs of adrenal suppression if maternal use was extensive near term. |
| Fertility Effects | No specific studies on fertility effects in humans. Animal studies with corticosteroids have shown impairment of fertility. The effect of topical clobetasol on human fertility is unknown. |
| Clinical Pearls | SERNIVO (clobetasol propionate) is a super-high-potency topical corticosteroid. Do not use for longer than 2 consecutive weeks. Limit total dosage to 50 g/week due to risk of HPA axis suppression. Avoid use on face, groin, or axillae. Not for ophthalmic use. Discontinue if irritation develops. |
| Patient Advice | Apply a thin layer to the affected skin only, once daily. · Do not use for more than 2 weeks in a row. · Avoid covering the treated area with bandages or other occlusive dressings unless directed by your doctor. · Do not get the medication in your eyes, mouth, or vagina. · Wash hands after applying, unless treating the hands. · Tell your doctor if you have a skin infection or if your condition worsens. · Do not use SERNIVO on your face, armpits, or groin area. |